Johnson & Johnson

Latest Headlines

Latest Headlines

Another generic settlement: Janssen, Watson agree on birth control pill

Janssen Pharmaceuticals, a unit of Johnson & Johnson, ($JNJ) will manufacture and supply generics maker Watson Pharmaceuticals ($WPI) with an authorized generic version of its oral contraceptive...

NICE rejects J&J's Zytiga as too expensive

The U.K.'s cost-effectiveness gatekeepers want to shut out Johnson & Johnson's ($JNJ) new prostate cancer pill. The National Institute for Health and Clinical Excellence issued draft...

Executive suite not spared in J&J reorg tied to quality concerns

Management at the factory level feel the heat under any FDA consent decree, but a shake-up at Johnson & Johnson ($JNJ) this week showed that the pressure can extend into the executive suite. Two...

FDA's new-drug approvals of 2011

2011 was a big year for drugmakers seeking to get their innovative products approved, as the FDA blessed 30 new drugs, a 7-year high. Among the lucky ones were Johnson & Johnson ($JNJ) and

WSJ: Another executive shake-up at J&J's McNeil unit

Johnson & Johnson ($JNJ) is taking an eraser to its McNeil Consumer Healthcare org chart again. Less than 12 months after a management shake-up put them in positions crucial to a McNeil

Gutted J&J consumer healthcare plant another year from reopening

Johnson & Johnson ($JNJ) will continue to ramp up its supply of over-the-counter drugs this year but it will be another year before its key manufacturing facility in Fort Washington, PA, will...

U.K. regulators launch metal hip investigation

Anxiety is likely on the rise this week among the more than 30,000 British patients who have metal-on-metal hip replacements. That's because the U.K. regulators have launched an investigation as...

13 Big Pharmas to collaborate on $785M fight against neglected diseases

Top executives from a slate of the world's biggest pharma companies will be rubbing shoulders with Bill Gates today as they roll out an ambitious plan to join hands on a $785 million effort to...

J&J, Stryker execs predict elective surgeries to rebound

Johnson & Johnson ($JNJ) and Stryker ($SYK) executives are predicting a rebound in elective surgeries as patients decide to undergo procedures they've been putting off due to the economy.

Little 'oomph' in J&J's results as forecasts fall short

Johnson & Johnson ($JNJ) delivered a double whammy with its latest financial announcement: Fourth-quarter earnings dropped by 89%, thanks to litigation and a product recall, and profit forecasts